Katherine Matthay, MD

Dr. Katherine Matthay is the chief of Pediatric Hematology-Oncology at UCSF Benioff Children's Hospital and has been focused for more than 20 years on translational research in neuroblastoma, a deadly childhood cancer. At UCSF, she has developed and led multiple trials using a unique targeted radiopharmaceutical, 131I-MIBG for neuroblastoma.

Dr. Matthay also leads the UCSF Pediatric Malignancies Program and an NIH funded Phase I New Approaches to Neuroblastoma Therapy consortium (NANT) for treatment of relapsed and resistant neuroblastoma.
Websites

  1. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA. Editor's Note: Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma. Cancer research 2024. PMID: 39350668


  2. Kumar P, Koach J, Nekritz E, Mukherjee S, Braun BS, DuBois SG, Nasholm N, Haas-Kogan D, Matthay KK, Weiss WA, Gustafson C, Seo Y. Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. EJNMMI research 2024. PMID: 38869684


  3. Barr EK, Naranjo A, Twist CJ, Tenney SC, Schmidt ML, London WB, Gastier-Foster J, Adkins ES, Mattei P, Handler MH, Matthay KK, Park JR, Maris JM, Desai AV, Cohn SL. Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531. Pediatric blood & cancer 2024. PMID: 38822537


  4. Kumar P, Willard VW, Embry L, Naranjo A, LaBarre B, Matthay KK, de Alarcon PA. Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group. Pediatric blood & cancer 2024. PMID: 38689540


  5. Huang M, Fang W, Farrel A, Li L, Chronopoulos A, Nasholm N, Cheng B, Zheng T, Yoda H, Barata MJ, Porras T, Miller ML, Zhen Q, Ghiglieri L, McHenry L, Wang L, Asgharzadeh S, Park J, Gustafson WC, Matthay KK, Maris JM, Weiss WA. ALK upregulates POSTN and WNT signaling to drive neuroblastoma. Cell reports 2024. PMID: 38451815


  6. Kumar P, Koach J, Nekritz E, Mukherjee S, Braun BS, DuBois SG, Nasholm N, Haas-Kogan D, Matthay KK, Weiss WA, Gustafson C, Seo Y. Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. Research square 2024. PMID: 38313265


  7. Hogarty MD, Ziegler DS, Franson A, Chi YY, Tsao-Wei D, Liu K, Vemu R, Gerner EW, Bruckheimer E, Shamirian A, Hasenauer B, Balis FM, Groshen S, Norris MD, Haber M, Park JR, Matthay KK, Marachelian A. Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial. British journal of cancer 2024. PMID: 38200233


  8. Chang D, Oh T, Roland JL, Matthay KK, Vo KT, Edwards CS, Sun PP, Auguste KI, Gupta N. Pediatric neuroblastoma with intraspinal extension: the role of surgical management. Journal of neurosurgery. Pediatrics 2023. PMID: 38100763


  9. Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma. Pediatric blood & cancer 2023. PMID: 37885116


  10. Rosenberg MI, Greenstein E, Buchkovich M, Peres A, Santoni-Rugiu E, Yang L, Mikl M, Vaksman Z, Gibbs DL, Reshef D, Salovin A, Irwin MS, Naranjo A, Ulitsky I, de Alarcon PA, Matthay KK, Weigman V, Yaari G, Panzer JA, Friedman N, Maris JM. Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma. Cell reports 2023. PMID: 37537844


  11. Streby KA, Parisi MT, Shulkin BL, LaBarre B, Bagatell R, Diller L, Grupp SA, Matthay KK, Voss SD, Yu AL, London WB, Park JR, Yanik GA, Naranjo A. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatric blood & cancer 2023. PMID: 37199022


  12. Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Moss? YP. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nature medicine 2023. PMID: 37012551


  13. Campbell K, Groshen S, Evans AC, Wilson S, Sebastian A, Loots GG, Marachelian A, Armant M, Pal S, Haas-Kogan DA, Park JR, Granger M, Matthay KK, Coleman MA, DuBois SG. Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma. International journal of radiation oncology, biology, physics 2022. PMID: 36526235


  14. Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer 2022. PMID: 36101004


  15. Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022. PMID: 35839426


  16. Qiu B, Matthay KK. Advancing therapy for neuroblastoma. 2022. PMID: 35614230


  17. Vo KT, DuBois SG, Neuhaus J, Braunstein SE, Weil BR, Naranjo A, Irtan S, Balaguer J, Matthay KK. Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. 2022. PMID: 35188340


  18. Evans AC, Setzkorn T, Edmondson DA, Segelke H, Wilson PF, Matthay KK, Granger MM, Marachelian A, Haas-Kogan DA, DuBois SG, Coleman MA. Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. 2021. PMID: 34673986


  19. Matthay KK, Hylton J, Penumarthy N, Khattab M, Soh SY, Nguyen HTK, Alcasabas AP, Fawzy M, Saab R, Khan MS, Ghandour K, Chantada G, Parikh NS, Faulkner L, Lam CG, Howard SC. Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries. 2022. PMID: 35084087


  20. Fishel Ben Kenan R, Polishchuk AL, Hawkins RA, Braunstein SE, Matthay KK, DuBois SG, Haas-Kogan DA. Anatomic patterns of relapse and progression following treatment with 131 I-MIBG in relapsed or refractory neuroblastoma. 2021. PMID: 34662499


  21. DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021. PMID: 34270348


  22. Weiss BD, Yanik G, Naranjo A, Zhang FF, Fitzgerald W, Shulkin BL, Parisi MT, Russell H, Grupp S, Pater L, Mattei P, Mosse Y, Lai HA, Jarzembowski JA, Shimada H, Villablanca JG, Giller R, Bagatell R, Park JR, Matthay KK. A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. Pediatric blood & cancer 2021. PMID: 34028986


  23. Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical cancer research : an official journal of the American Association for Cancer Research 2021. PMID: 33504555


  24. Temple WC, Vo KT, Matthay KK, Balliu B, Coleman C, Michlitsch J, Phelps A, Behr S, Zapala MA. Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma. Cancer medicine 2020. PMID: 33314708


  25. Lavergne V, Sabnis A, Tupule A, Davidson PR, Kline C, Matthay K, Nicolaides T, Goldsby R, Braunstein S, Fogh SE, Sneed PK, Menzel P, Nakamura A, DuBois SG, Haas-Kogan DA, Nakamura JL. Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. Journal of pediatric hematology/oncology 2020. PMID: 31815884


  26. Aboian MS, Huang SY, Hernandez-Pampaloni M, Hawkins RA, VanBrocklin HF, Huh Y, Vo KT, Gustafson WC, Matthay KK, Seo Y. 124I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020. PMID: 32414950


  27. Oldridge DA, Truong B, Russ D, DuBois SG, Vaksman Z, Mosse YP, Diskin SJ, Maris JM, Matthay KK. Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma. Journal of the National Cancer Institute 2019. PMID: 30793172


  28. Chévez-Barrios P, Eagle RC, Krailo M, Piao J, Albert DM, Gao Y, Vemuganti G, Ali MJ, Khetan V, Honavar SG, O'Brien J, Leahey AM, Matthay K, Meadows A, Chintagumpala M. Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019. PMID: 31539297


  29. Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019. PMID: 31386611


  30. Sznewajs A, Pon E, Matthay KK. Congenital malformation syndromes associated with peripheral neuroblastic tumors: A systematic review. Pediatric blood & cancer 2019. PMID: 31264798


  31. Tolbert VP, Dvorak CC, Golden C, Vissa M, El-Haj N, Perwad F, Matthay KK, Vo KT. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019. PMID: 31199983


  32. Campbell K, Shyr D, Bagatell R, Fischer M, Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, London WB, DuBois SG. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric blood & cancer 2019. PMID: 31115156


  33. Braunstein SE, London WB, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C, Park JR, La Quaglia MP, Haas-Kogan DA. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatric blood & cancer 2019. PMID: 30968542


  34. Seo Y, Huh Y, Huang SY, Hernandez-Pampaloni JM, Hawkins RA, Gustafson WC, Vo KT, Matthay KK. Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT. Medical physics 2019. PMID: 30761545


  35. Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018. PMID: 30444686


  36. Matthay KK. Interleukin 2 plus anti-GD2 immunotherapy: helpful or harmful? The Lancet. Oncology 2018. PMID: 30442498


  37. DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2018. PMID: 30093449


  38. Kumar P, Gill RM, Phelps A, Tulpule A, Matthay K, Nicolaides T. Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives. Cureus 2018. PMID: 29946497


  39. Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric blood & cancer 2018. PMID: 29603591


  40. Tolbert VP, Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell and tissue research 2018. PMID: 29572647


  41. Villablanca JG, Ji L, Shapira-Lewinson A, Marachelian A, Shimada H, Hawkins RA, Pampaloni M, Lai H, Goodarzian F, Sposto R, Park JR, Matthay KK. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatric blood & cancer 2018. PMID: 29350464


  42. Kondapavulur S, Cooke DL, Kao A, Amans MR, Alexander M, Darflinger R, Dowd CF, Higashida RT, Damato B, Halbach VV, Matthay KK, Hetts SW. Estimation of intra-arterial chemotherapy distribution to the retina in pediatric retinoblastoma patients using quantitative digital subtraction angiography. Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences 2018. PMID: 29343147


  43. de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. The Lancet. Child & adolescent health 2017. PMID: 29376112


  44. Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2017. PMID: 28972044


  45. Ladenstein R, Lambert B, Pötschger U, Castellani MR, Lewington V, Bar-Sever Z, Oudoux A, Sliwinska A, Taborska K, Biassoni L, Yanik GA, Naranjo A, Parisi MT, Shulkin BL, Nadel H, Gelfand MJ, Matthay KK, Park JR, Kreissman SG, Valteau-Couanet D, Boubaker A. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. European journal of nuclear medicine and molecular imaging 2017. PMID: 28940046


  46. Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, Ladenstein RL, Poetschger U, Boubaker A, Valteau-Couanet D, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, Kaminska A, Kreissman SG, Shulkin BL, Matthay KK. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017. PMID: 28887399


  47. Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer 2017. PMID: 28696504


  48. Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R, Seeger RC. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clinical cancer research : an official journal of the American Association for Cancer Research 2017. PMID: 28559462


  49. Campbell K, Karski EE, Olow A, Edmondson DA, Kohlgruber AC, Coleman M, Haas-Kogan DA, Matthay KK, DuBois SG. Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. International journal of radiation oncology, biology, physics 2017. PMID: 28871998


  50. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017. PMID: 28471719


  51. DuBois SG, Mody R, Naranjo A, Van Ryn C, Russ D, Oldridge D, Kreissman S, Baker DL, Parisi M, Shulkin BL, Bai H, Diskin SJ, Batra V, Maris JM, Park JR, Matthay KK, Yanik G. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatric blood & cancer 2017. PMID: 28383813


  52. Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG. Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget 2017. PMID: 27793021


  53. Dinh T, Truong B, Matthay KK, DuBois SG. Comparison of Clinical Features and Outcomes in Patients With Bilateral Versus Unilateral Adrenal Neuroblastoma. Journal of pediatric hematology/oncology 2017. PMID: 27820129


  54. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. Neuroblastoma. Nature reviews. Disease primers 2016. PMID: 27830764


  55. Li R, Polishchuk A, DuBois S, Hawkins R, Lee SW, Bagatell R, Shusterman S, Hill-Kayser C, Al-Sayegh H, Diller L, Haas-Kogan DA, Matthay KK, London WB, Marcus KJ. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. International journal of radiation oncology, biology, physics 2016. PMID: 28068235


  56. Huibregtse KE, Vo KT, DuBois SG, Fetzko S, Neuhaus J, Batra V, Maris JM, Weiss B, Marachelian A, Yanik GA, Matthay KK. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. European journal of cancer (Oxford, England : 1990) 2016. PMID: 27573428


  57. Edmondson DA, Karski EE, Kohlgruber A, Koneru H, Matthay KK, Allen S, Hartmann CL, Peterson LE, DuBois SG, Coleman MA. Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide. Radiation research 2016. PMID: 27556353


  58. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. European journal of cancer (Oxford, England : 1990) 2016. PMID: 27434878


  59. Lee JS, Matthay K, DuBois SG, Roy-Burman A. Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy? Pediatric blood & cancer 2016. PMID: 27394054


  60. Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Parisi MT, Shulkin BL, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG. Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. European journal of nuclear medicine and molecular imaging 2016. PMID: 27044383


  61. Vo KT, Matthay KK, DuBois SG. Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clinical sarcoma research 2016. PMID: 27274393


  62. Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatric blood & cancer 2016. PMID: 27092812


  63. DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016. PMID: 26884555


  64. Vo KT, Edwards JV, Epling CL, Sinclair E, Hawkins DS, Grier HE, Janeway KA, Barnette P, McIlvaine E, Krailo MD, Barkauskas DA, Matthay KK, Womer RB, Gorlick RG, Lessnick SL, Mackall CL, DuBois SG. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2016. PMID: 26861456


  65. Balkin EM, Thompson D, Colson KE, Lam CG, Matthay KK. Physician Perspectives on Palliative Care for Children With Neuroblastoma: An International Context. Pediatric blood & cancer 2016. PMID: 26784890


  66. Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer 2015. PMID: 26709890


  67. Lee JS, Wu R, Wong T, DuBois SG, Matthay K, Gustafson C, Hawkins R, Roy-Burman A. Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma. Pediatric blood & cancer 2015. PMID: 26585842


  68. Cohler C, Jumanne S, Kaijage J, DuBois SG, Scanlan P, Matthay KK. Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania. Pediatric blood & cancer 2015. PMID: 26529141


  69. Trieu M, DuBois SG, Pon E, Nardo L, Hawkins RA, Marachelian A, Twist CJ, Park JR, Matthay KK. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatric blood & cancer 2015. PMID: 26506090


  70. Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. European journal of nuclear medicine and molecular imaging 2015. PMID: 26338179


  71. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015. PMID: 26304901


  72. Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). European journal of cancer (Oxford, England : 1990) 2015. PMID: 26254811


  73. Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatric blood & cancer 2015. PMID: 26153194


  74. Huang SY, Bolch WE, Lee C, Van Brocklin HF, Pampaloni MH, Hawkins RA, Sznewajs A, DuBois SG, Matthay KK, Seo Y. Patient-specific dosimetry using pretherapy [¹²4I]m-iodobenzylguanidine ([¹²4I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma. Molecular imaging and biology 2015. PMID: 25145966


  75. Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB, Matthay KK, International Society of Pediatric Oncology. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatric blood & cancer 2015. PMID: 25810263


  76. DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2015. PMID: 25695691


  77. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015. PMID: 25639769


  78. DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, Courtier J, Mosse YP, Matthay KK. Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. British journal of cancer 2015. PMID: 25602966


  79. Matthay KK, London WB, Maris J, Adamson PC, Park JR. Reply to N.-K.V. Cheung et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014. PMID: 25403223


  80. Thampi S, Matthay KK, Boscardin WJ, Goldsby R, DuBois SG. Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma. Sarcoma 2014. PMID: 25294959


  81. Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer cell 2014. PMID: 25175806


  82. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014. PMID: 25154816


  83. Zinter MS, DuBois SG, Spicer A, Matthay K, Sapru A. Pediatric cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit. Intensive care medicine 2014. PMID: 25023526


  84. Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatric blood & cancer 2014. PMID: 25044743


  85. Baggott C, Cooper BA, Marina N, Matthay KK, Miaskowski C. Symptom assessment in pediatric oncology: how should concordance between children's and parents' reports be evaluated? Cancer nursing 2014. PMID: 24936750


  86. Polishchuk AL, Li R, Hill-Kayser C, Little A, Hawkins RA, Hamilton J, Lau M, Tran HC, Strahlendorf C, Lemons RS, Weinberg V, Matthay KK, DuBois SG, Marcus KJ, Bagatell R, Haas-Kogan DA. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. International journal of radiation oncology, biology, physics 2014. PMID: 24867534


  87. Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC research notes 2014. PMID: 24755475


  88. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014. PMID: 24663047


  89. Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, Cohn SL, Pearson AD, London WB, Matthay KK. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatric blood & cancer 2013. PMID: 24038992


  90. Kersten E, Scanlan P, Dubois SG, Matthay KK. Current treatment and outcome for childhood acute leukemia in Tanzania. Pediatric blood & cancer 2013. PMID: 24039163


  91. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. The Lancet. Oncology 2013. PMID: 23890779


  92. Thampi S, Matthay KK, Goldsby R, DuBois SG. Adverse impact of regional lymph node involvement in osteosarcoma. European journal of cancer (Oxford, England : 1990) 2013. PMID: 23867123


  93. Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatric blood & cancer 2013. PMID: 23813912


  94. Thampi S, Hetts SW, Cooke DL, Stewart PJ, Robbins E, Banerjee A, Dubois SG, Char D, Halbach V, Matthay K. Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution. Clinical ophthalmology (Auckland, N.Z.) 2013. PMID: 23818751


  95. Wong T, Matthay KK, Boscardin WJ, Hawkins RA, Brakeman PR, DuBois SG. Acute changes in blood pressure in patients with neuroblastoma treated with ¹³¹I-metaiodobenzylguanidine (MIBG). Pediatric blood & cancer 2013. PMID: 23613447


  96. DuBois SG, Matthay KK. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 2013. PMID: 23474635


  97. Mueller S, Bhargava S, Molinaro AM, Yang X, Kolkowitz I, Olow A, Wehmeijer N, Orbach S, Chen J, Matthay KK, Haas-Kogan DA. Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer research 2013. PMID: 23482742


  98. Depasse J, Caniza MA, Quessar A, Khattab M, Hessissen L, Ribeiro R, Cherkaoui S, Benchekroun S, Matthay KK. Infections in hospitalized children and young adults with acute leukemia in Morocco. Pediatric blood & cancer 2013. PMID: 23450753


  99. Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013. PMID: 23440556


  100. Green DM, Kun LE, Matthay KK, Meadows AT, Meyer WH, Meyers PA, Spunt SL, Robison LL, Hudson MM. Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pediatric blood & cancer 2013. PMID: 23418018


  101. Matthay KK. Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption. Clinical cancer research : an official journal of the American Association for Cancer Research 2012. PMID: 23209029


  102. Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, VanBrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Molecular imaging and biology 2012. PMID: 22382618


  103. French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatric blood & cancer 2012. PMID: 23024113


  104. Dubois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, Martinez D, Pawel B, Yanik G, Naranjo A, London WB, Kreissman S, Baker D, Attiyeh E, Hogarty MD, Maris JM, Giacomini K, Matthay KK. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. International journal of molecular imaging 2012. PMID: 23050139


  105. Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. British journal of cancer 2012. PMID: 22976801


  106. Karski EE, Matthay KK, Neuhaus JM, Goldsby RE, Dubois SG. Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer epidemiology 2012. PMID: 22959474


  107. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012. PMID: 22927533


  108. Applebaum MA, Sambrano E, Lee S, Goldsby R, Matthay KK, DuBois SG. Evaluation of plasma annexin V levels in children and young adults with solid tumors. The International journal of biological markers 2012. PMID: 22610756


  109. Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012. PMID: 22700000


  110. Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012. PMID: 22589483


  111. Porzig A, Matthay KK, Dubois S, Pampaloni M, Damon L, Hawkins R, Goldsby R, Hollinger F, Fitzgerald P. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2012. PMID: 22588707


  112. Marachelian A, Shimada H, Sano H, Jackson H, Stein J, Sposto R, Matthay KK, Baker D, Villablanca JG. The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. Pediatric blood & cancer 2012. PMID: 22493777


  113. Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012. PMID: 22529259


  114. DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2012. PMID: 22421195


  115. Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Science translational medicine 2012. PMID: 22218692


  116. Baggott C, Cooper BA, Marina N, Matthay KK, Miaskowski C. Symptom cluster analyses based on symptom occurrence and severity ratings among pediatric oncology patients during myelosuppressive chemotherapy. Cancer nursing 2012. PMID: 21921793


  117. Sharib JM, Cyrus J, Horvai A, Gray Hazard FK, Neuhaus J, Matthay KK, Goldsby R, Marina N, DuBois SG. Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatric blood & cancer 2011. PMID: 22180320


  118. Angelini P, London WB, Cohn SL, Pearson AD, Matthay KK, Monclair T, Ambros PF, Shimada H, Leuschner I, Peuchmaur M, Irwin MS, Baruchel S. Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project. European journal of cancer (Oxford, England : 1990) 2011. PMID: 22137163


  119. Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011. PMID: 22010014


  120. Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011. PMID: 21969516


  121. Gustafson WC, Matthay KK. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma. Expert review of neurotherapeutics 2011. PMID: 21955198


  122. DuBois SG, Goldsby R, Segal M, Woo J, Copren K, Kane JP, Pullinger CR, Matthay KK, Witte J, Lessnick SL, Robison LL, Bhatia S, Strong LC. Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study. Pediatric blood & cancer 2011. PMID: 21793187


  123. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011. PMID: 21768459


  124. Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T, International Neuroblastoma Risk Group Project. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011. PMID: 21586679


  125. Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, Haas-Kogan DA. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer letters 2011. PMID: 21497989


  126. More SS, Itsara M, Yang X, Geier EG, Tadano MK, Seo Y, Vanbrocklin HF, Weiss WA, Mueller S, Haas-Kogan DA, Dubois SG, Matthay KK, Giacomini KM. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clinical cancer research : an official journal of the American Association for Cancer Research 2011. PMID: 21421857


  127. Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer 2011. PMID: 21387264


  128. Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer chemotherapy and pharmacology 2011. PMID: 21340605


  129. Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG, Yanik GA. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric blood & cancer 2011. PMID: 21328522


  130. Applebaum MA, Worch J, Matthay KK, Goldsby R, Neuhaus J, West DC, Dubois SG. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer 2011. PMID: 21692057


  131. Worch J, Cyrus J, Goldsby R, Matthay KK, Neuhaus J, DuBois SG. Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011. PMID: 21212061


  132. Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Rubie H, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson AD, Cohn SL, London WB. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. European journal of cancer (Oxford, England : 1990) 2010. PMID: 21112770


  133. Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatric blood & cancer 2010. PMID: 21671363


  134. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. The New England journal of medicine 2010. PMID: 20879881


  135. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK, Children’s Oncology Group. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. The New England journal of medicine 2010. PMID: 20879880


  136. Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, Matthay KK. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatric blood & cancer 2010. PMID: 20830775


  137. Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, Hawkins RA, Dannoon SF, VanBrocklin HF, Itsara M, Weiss WA, Yang X, Haas-Kogan DA, Matthay KK, Seo Y. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Medical physics 2010. PMID: 20964203


  138. Baggott C, Dodd M, Kennedy C, Marina N, Matthay KK, Cooper BA, Miaskowski C. Changes in children's reports of symptom occurrence and severity during a course of myelosuppressive chemotherapy. Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses 2010. PMID: 20739586


  139. Worch J, Matthay KK, Neuhaus J, Goldsby R, DuBois SG. Osteosarcoma in children 5 years of age or younger at initial diagnosis. Pediatric blood & cancer 2010. PMID: 20582978


  140. London WB, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, Matthay KK, Castleberry RP, Diller L. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010. PMID: 20660830


  141. Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, Pearson AD, Cohn SL. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. British journal of cancer 2010. PMID: 20424613


  142. Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R, London WB, Yap JS, Kreissman SG. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Pediatric blood & cancer 2010. PMID: 20049927


  143. Baggott CR, Dodd M, Kennedy C, Marina N, Matthay KK, Cooper B, Miaskowski C. An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2010. PMID: 20157746


  144. Worch J, Matthay KK, Neuhaus J, Goldsby R, DuBois SG. Ethnic and racial differences in patients with Ewing sarcoma. Cancer 2010. PMID: 20052725


  145. Dubois SG, Epling CL, Teague J, Matthay KK, Sinclair E. Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatric blood & cancer 2010. PMID: 19711435


  146. Hsieh MH, Meng MV, Walsh TJ, Matthay KK, Baskin LS. Increasing incidence of neuroblastoma and potentially higher associated mortality of children from nonmetropolitan areas: analysis of the surveillance, epidemiology, and end results database. Journal of pediatric hematology/oncology 2009. PMID: 19875967


  147. Mueller S, Matthay KK. Neuroblastoma: biology and staging. Current oncology reports 2009. PMID: 19840520


  148. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Mari Aparici C, Carlson D, Maris J, Hawkins R, Matthay KK. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009. PMID: 19805691


  149. Okamatsu C, London WB, Naranjo A, Hogarty MD, Gastier-Foster JM, Look AT, LaQuaglia M, Maris JM, Cohn SL, Matthay KK, Seeger RC, Saji T, Shimada H. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG. Pediatric blood & cancer 2009. PMID: 19530234


  150. Sutton EJ, Tong RT, Gillis AM, Henning TD, Weinberg VA, Boddington S, Haas-Kogan DA, Matthay K, Sha V, Gooding C, Coakley FV, Daldrup-Link H. Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy. Pediatric radiology 2009. PMID: 19763559


  151. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009. PMID: 19636009


  152. Jabbari S, Andolino D, Weinberg V, Missett BT, Law J, Wara WM, O'Donnell RJ, Matthay KK, DuBois SG, Goldsby R, Haas-Kogan DA. Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. International journal of radiation oncology, biology, physics 2009. PMID: 19410386


  153. Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, Pearson AD, Matthay KK, International neuroblastoma Risk Group Task Force. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. British journal of cancer 2009. PMID: 19401690


  154. Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009. PMID: 19171714


  155. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009. PMID: 19171716


  156. Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009. PMID: 19171709


  157. Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK, Children's Oncology Group. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatric blood & cancer 2009. PMID: 18937318


  158. Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008. PMID: 19047298


  159. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 2008. PMID: 19088694


  160. Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, Monclair T, Ambros PF, Cohn SL, International Neuroblastoma Risk Group. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008. PMID: 19047282


  161. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008. PMID: 19047291


  162. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008. PMID: 19047290


  163. Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, Ellis KJ, Renbarger J, Berg SL. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer chemotherapy and pharmacology 2008. PMID: 19020877


  164. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, Weiss WA. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia (New York, N.Y.) 2008. PMID: 18953436


  165. Dubois SG, London WB, Zhang Y, Matthay KK, Monclair T, Ambros PF, Cohn SL, Pearson A, Diller L. Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric blood & cancer 2008. PMID: 18649370


  166. Kleis M, Daldrup-Link H, Matthay K, Goldsby R, Lu Y, Schuster T, Schreck C, Chu PW, Hawkins RA, Franc BL. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. European journal of nuclear medicine and molecular imaging 2008. PMID: 18719909


  167. Koral KF, Huberty JP, Frame B, Matthay KK, Maris JM, Regan D, Normolle D, Yanik GA. Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma. European journal of nuclear medicine and molecular imaging 2008. PMID: 18682939


  168. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nuclear Medicine and Biology 2008. PMID: 18707633


  169. Matthay KK. Chemotherapy for neuroblastoma: does it hit the target? The Lancet. Oncology 2008. PMID: 18308243


  170. Meyer GE, Chesler L, Liu D, Gable K, Maddux BA, Goldenberg DD, Youngren JF, Goldfine ID, Weiss WA, Matthay KK, Rosenthal SM. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. Journal of cellular biochemistry 2007. PMID: 17486636


  171. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML, Children's Oncology Group. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics 2007. PMID: 17974716


  172. Adamson PC, Matthay KK, O'Brien M, Reaman GH, Sato JK, Balis FM. A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study. Pediatric blood & cancer 2007. PMID: 16900483


  173. Gillis AM, Sutton E, Dewitt KD, Matthay KK, Weinberg V, Fisch BM, Chan A, Gooding C, Daldrup-Link H, Wara WM, Farmer DL, Harrison MR, Haas-Kogan D. Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. International journal of radiation oncology, biology, physics 2007. PMID: 17517478


  174. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007. PMID: 17369569


  175. Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B, Maris JM, Yanik G, Hawkins RA, Matthay KK. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatric blood & cancer 2006. PMID: 16444675


  176. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. Journal of the National Cancer Institute 2006. PMID: 16954472


  177. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer research 2006. PMID: 16912192


  178. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Dela Cruz F, Jahan TM, Linker CA, Damon L, Matthay KK. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Annals of the New York Academy of Sciences 2006. PMID: 17102115


  179. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer research 2006. PMID: 16778177


  180. Sano H, Bonadio J, Gerbing RB, London WB, Matthay KK, Lukens JN, Shimada H. International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. European journal of cancer (Oxford, England : 1990) 2006. PMID: 16624549


  181. Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM, Children's Oncology Group. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2006. PMID: 16551859


  182. Matthay KK. Is liver metastasis in neuroblastoma an indication for treatment reduction? Pediatric blood & cancer 2006. PMID: 16261577


  183. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006. PMID: 16421427


  184. Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM, Children's Oncology Group. Chromosome 1p and 11q deletions and outcome in neuroblastoma. The New England journal of medicine 2005. PMID: 16306521


  185. Matthay KK, Blaes F, Hero B, Plantaz D, De Alarcon P, Mitchell WG, Pike M, Pistoia V. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer letters 2005. PMID: 15922508


  186. London WB, Boni L, Simon T, Berthold F, Twist C, Schmidt ML, Castleberry RP, Matthay KK, Cohn SL, De Bernardi B. The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer letters 2005. PMID: 16024170


  187. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005. PMID: 16116153


  188. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005. PMID: 16116154


  189. Howard JP, Maris JM, Kersun LS, Huberty JP, Cheng SC, Hawkins RA, Matthay KK. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatric blood & cancer 2005. PMID: 15490487


  190. Kobayashi C, Monforte-Munoz HL, Gerbing RB, Stram DO, Matthay KK, Lukens JN, Seeger RC, Shimada H. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Cancer 2005. PMID: 15549714


  191. Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer 2004. PMID: 15386308


  192. DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004. PMID: 15197208


  193. Adkins ES, Sawin R, Gerbing RB, London WB, Matthay KK, Haase GM. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. Journal of pediatric surgery 2004. PMID: 15185228


  194. Schatz J, Kramer JH, Ablin AR, Matthay KK. Visual attention in long-term survivors of leukemia receiving cranial radiation therapy. Journal of the International Neuropsychological Society : JINS 2004. PMID: 15012841


  195. Goldsby RE, Matthay KK. Neuroblastoma: evolving therapies for a disease with many faces. Paediatric drugs 2004. PMID: 15035651


  196. Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, Gerbing RB, Stram DO, Lukens JN, Matthay KK, Shimada H. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003. PMID: 14601099


  197. Machatschek J, Duda J, Matthay K, Cowan M, Horn B. Immune reconstitution, infectious complications and post transplant supportive care measures after autologous blood and marrow transplantation in children. Bone marrow transplantation 2003. PMID: 13130316


  198. Moore IM, Challinor J, Pasvogel A, Matthay K, Hutter J, Kaemingk K. Online exclusive: behavioral adjustment of children and adolescents with cancer: teacher, parent, and self-report. Oncology nursing forum 2003. PMID: 12949601


  199. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer letters 2003. PMID: 12880980


  200. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003. PMID: 12872341


  201. Matthay KK, Brisse H, Couanet D, Couturier J, Bénard J, Mosseri V, Edeline V, Lumbroso J, Valteau-Couanet D, Michon J. Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer 2003. PMID: 12833468


  202. Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, Valteau-Couanet D, Hartmann O, Michon J. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003. PMID: 12829667


  203. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. Journal of pediatric hematology/oncology 2003. PMID: 12847321


  204. McHale CM, Wiemels JL, Zhang L, Ma X, Buffler PA, Feusner J, Matthay K, Dahl G, Smith MT. Prenatal origin of childhood acute myeloid leukemias harboring chromosomal rearrangements t(15;17) and inv(16). Blood 2003. PMID: 12756163


  205. Haas-Kogan DA, Swift PS, Selch M, Haase GM, Seeger RC, Gerbing RB, Stram DO, Matthay KK. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. International journal of radiation oncology, biology, physics 2003. PMID: 12694821


  206. Challinor J, Moore IK, Kramer R, Pasvogel A, Leung K, Amylon M, Hutter J, Matthay K. Development and testing of the School Competency Assessment Scale. Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses 2003. PMID: 12709932


  207. Ma X, Buffler PA, Selvin S, Matthay KK, Wiencke JK, Wiemels JL, Reynolds P. Daycare attendance and risk of childhood acute lymphoblastic leukaemia. British journal of cancer 2002. PMID: 11986774


  208. Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, Hubers D, Spalding S, Braun T, Ferrara JL, Hutchinson RJ. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002. PMID: 11956276


  209. DuBois SG, Etzell JE, Matthay KK, Robbins E, Banerjee A. Pediatric acute blastic natural killer cell leukemia. Leukemia & lymphoma 2002. PMID: 12153184


  210. Horn B, Reiss U, Matthay K, McMillan A, Cowan M. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma. Bone marrow transplantation 2002. PMID: 11919731


  211. Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001. PMID: 11745206


  212. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001. PMID: 11696644


  213. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, Gerbing RB, Stram DO, Lukens JN, Matthay KK. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001. PMID: 11745303


  214. Hayward K, Jeremy RJ, Jenkins S, Barkovich AJ, Gultekin SH, Kramer J, Crittenden M, Matthay KK. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. The Journal of pediatrics 2001. PMID: 11598603


  215. Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Matthay KK. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Medical and pediatric oncology 2001. PMID: 11344492


  216. Cooper R, Khakoo Y, Matthay KK, Lukens JN, Seeger RC, Stram DO, Gerbing RB, Nakagawa A, Shimada H. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Medical and pediatric oncology 2001. PMID: 11344493


  217. Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, Favrot MC, Delattre O, Michon J, Bénard J, Hartmann O, Nicholson JC, Ross FM, Brinkschmidt C, Laureys G, Caron H, Matthay KK, Feuerstein BG, Speleman F. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. International journal of cancer 2001. PMID: 11267980


  218. Bertucio CS, Wara WM, Matthay KK, Ablin AR, Johnston JO, O'Donnell RJ, Weinberg V, Haas-Kogan DA. Functional and clinical outcomes of limb-sparing therapy for pediatric extremity sarcomas. International journal of radiation oncology, biology, physics 2001. PMID: 11172960


  219. Kammen BF, Matthay KK, Pacharn P, Gerbing R, Brasch RC, Gooding CA. Pulmonary metastases at diagnosis of neuroblastoma in pediatric patients: CT findings and prognosis. AJR. American journal of roentgenology 2001. PMID: 11222220


  220. Tang HR, Da Silva AJ, Matthay KK, Price DC, Huberty JP, Hawkins RA, Hasegawa BH. Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001. PMID: 11216522


  221. Maris JM, Guo C, White PS, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Medical and pediatric oncology 2001. PMID: 11464895


  222. Espy KA, Moore IM, Kaufmann PM, Kramer JH, Matthay K, Hutter JJ. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. Journal of pediatric psychology 2001. PMID: 11145727


  223. Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, Rajalingam V, Gerbing R, Stram DO, Matthay KK, Seeger RC, Brodeur GM. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Medical and pediatric oncology 2001. PMID: 11464900


  224. Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O'Brien JM. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Archives of ophthalmology (Chicago, Ill. : 1960) 2001. PMID: 11146725


  225. Thompson PM, Seifried BA, Kyemba SK, Jensen SJ, Guo C, Maris JM, Brodeur GM, Stram DO, Seeger RC, Gerbing R, Matthay KK, Matise TC, White PS. Loss of heterozygosity for chromosome 14q in neuroblastoma. Medical and pediatric oncology 2001. PMID: 11464899


  226. Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000. PMID: 11118469


  227. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000. PMID: 11118468


  228. Goto H, Keshelava N, Matthay KK, Lukens JN, Gerbing RB, Stram DO, Seeger RC, Reynolds CP. Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors. Medical and pediatric oncology 2000. PMID: 11107131


  229. Park JR, Slattery J, Gooley T, Hawkins D, Lindsley K, Villablanca JG, Matthay KK, Sanders JE. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Medical and pediatric oncology 2000. PMID: 11107155


  230. Choi LM, Kim NW, Zuo JJ, Gerbing R, Stram D, Lukens JN, Matthay KK, Seeger RC, Reynolds CP. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma. Medical and pediatric oncology 2000. PMID: 11107138


  231. Moore IM, Espy KA, Kaufmann P, Kramer J, Kaemingk K, Miketova P, Mollova N, Kaspar M, Pasvogel A, Schram K, Wara W, Hutter J, Matthay K. Cognitive consequences and central nervous system injury following treatment for childhood leukemia. Seminars in oncology nursing 2000. PMID: 11109272


  232. Matthay KK, Reynolds CP. Is there a role for retinoids to treat minimal residual disease in neuroblastoma? British journal of cancer 2000. PMID: 11027422


  233. Matthay KK. MYCN expression in neuroblastoma: A mixed message? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000. PMID: 11054431


  234. Umehara S, Nakagawa A, Matthay KK, Lukens JN, Seeger RC, Stram DO, Gerbing RB, Shimada H. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. Cancer 2000. PMID: 10964346


  235. Matthay KK, Stram D. Is adjuvant therapy ever warranted in localized neuroblastoma. Journal of pediatric hematology/oncology 2000. PMID: 11037848


  236. Antunes NL, Khakoo Y, Matthay KK, Seeger RC, Stram DO, Gerstner E, Abrey LE, Dalmau J. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. Journal of pediatric hematology/oncology 2000. PMID: 10959901


  237. Haas-Kogan DA, Fisch BM, Wara WM, Swift PS, Farmer DL, Harrison MR, Albanese C, Weinberg V, Matthay KK. Intraoperative radiation therapy for high-risk pediatric neuroblastoma. International journal of radiation oncology, biology, physics 2000. PMID: 10863069


  238. Fernandez MC, Krailo MD, Gerbing RR, Matthay KK. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma. Cancer 2000. PMID: 10870069


  239. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000. PMID: 10784629


  240. Schatz J, Kramer JH, Ablin A, Matthay KK. Processing speed, working memory, and IQ: a developmental model of cognitive deficits following cranial radiation therapy. Neuropsychology 2000. PMID: 10791859


  241. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, Matthay KK. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000. PMID: 10715296


  242. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000. PMID: 10653863


  243. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000. PMID: 10623689


  244. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. The New England journal of medicine 1999. PMID: 10519894


  245. Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM, Maris JM. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999. PMID: 10490829


  246. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999. PMID: 10421273


  247. Maris JM, Matthay KK. Molecular biology of neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999. PMID: 10561284


  248. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H, Gerbing R, Stram DO, Matthay KK. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. Journal of pediatric hematology/oncology 1999. PMID: 10363850


  249. Fernandez MC, Weiss B, Atwater S, Shannon K, Matthay KK. Congenital leukemia: successful treatment of a newborn with t(5;11)(q31;q23). Journal of pediatric hematology/oncology 1999. PMID: 10206463


  250. Matthay KK. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatric transplantation 1999. PMID: 10587975


  251. Challinor JM, Miaskowski CA, Franck LS, Slaughter RE, Matthay KK, Kramer RF, Veatch JJ, Paul SM, Amylon MD, Moore IM. Somatization, anxiety and depression as measures of health-related quality of life of children/adolescents with cancer. International journal of cancer. Supplement = Journal international du cancer. Supplement 1999. PMID: 10679871


  252. Goldberg SS, DeSantes K, Huberty JP, Price D, Hasegawa BH, Reynolds CP, Seeger RC, Hattner R, Matthay KK. Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Medical and pediatric oncology 1998. PMID: 9589082


  253. Matthay KK. Stage 4S neuroblastoma: what makes it special? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998. PMID: 9626196


  254. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, Black CT, Gerbing R, Haase GM, Stram DO, Swift P, Lukens JN. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998. PMID: 9552023


  255. Ozkaynak MF, Matthay K, Cairo M, Harris RE, Feig S, Reynolds CP, Buckley J, Villablanca JG, Seeger RC. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998. PMID: 9508176


  256. Loh K, Matthay KK, Hoover M, Bracho FA, Cortez AB, Conte FA, Albanese CT, Miller TR, Price DC, Flores AJ, Kaviani A, Shoback D. Hypercalcemia in malignant paraganglioma due to parathyroid hormone-related protein. Hormone research 1998. PMID: 9838243


  257. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998. PMID: 9440747


  258. Matthay KK. Neuroblastoma: biology and therapy. Oncology (Williston Park, N.Y.) 1997. PMID: 9436190


  259. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. Journal of endocrinological investigation 1997. PMID: 9492103


  260. Reynolds CP, Zuo JJ, Kim NW, Wang H, Lukens JN, Matthay KK, Seeger RC. Telomerase expression in primary neuroblastomas. European journal of cancer (Oxford, England : 1990) 1997. PMID: 9516826


  261. Castleberry RP, Pritchard J, Ambros P, Berthold F, Brodeur GM, Castel V, Cohn SL, De Bernardi B, Dicks-Mireaux C, Frappaz D, Haase GM, Haber M, Jones DR, Joshi VV, Kaneko M, Kemshead JT, Kogner P, Lee RE, Matthay KK, Michon JM, Monclair R, Roald BR, Seeger RC, Shaw PJ, Shuster JJ. The International Neuroblastoma Risk Groups (INRG): a preliminary report. European journal of cancer (Oxford, England : 1990) 1997. PMID: 9516864


  262. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997. PMID: 9217046


  263. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 1997. PMID: 9149032


  264. Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC, Feuerstein BG. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. The American journal of pathology 1997. PMID: 9006325


  265. Matthay KK. Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma. Bone marrow transplantation 1996. PMID: 8971402


  266. Donnelly LF, Rencken IO, Shardell K, Matthay KK, Miller CR, Vartanian RK, Gooding CA. Renal cell carcinoma after therapy for neuroblastoma. AJR. American journal of roentgenology 1996. PMID: 8819382


  267. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, Brodeur GM, Seeger RC. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996. PMID: 8823319


  268. Willis B, Ablin A, Weinberg V, Zoger S, Wara WM, Matthay KK. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996. PMID: 8683239


  269. Lang P, Vahlensieck M, Matthay KK, Johnston JO, Rosenau W, Gooding CA, Genant HK. Monitoring neovascularity as an indicator to response to chemotherapy in osteogenic and Ewing sarcoma using magnetic resonance angiography. Medical and pediatric oncology 1996. PMID: 8614366


  270. Chou RH, Wong GB, Kramer JH, Wara DW, Matthay KK, Crittenden MR, Swift PS, Cowan MJ, Wara WM. Toxicities of total-body irradiation for pediatric bone marrow transplantation. International journal of radiation oncology, biology, physics 1996. PMID: 8598361


  271. Haase GM, O'Leary MC, Stram DO, Lukens JN, Seeger RC, Shimada H, Matthay KK. Pelvic neuroblastoma--implications for a new favorable subgroup: a Children's Cancer Group experience. Annals of surgical oncology 1995. PMID: 8591082


  272. Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK, Seeger RC. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. Journal of the National Cancer Institute 1995. PMID: 7674334


  273. Lang P, Grampp S, Vahlensieck M, Johnston JO, Honda G, Rosenau W, Matthay KK, Peterfy C, Higgins CB, Genant HK. Primary bone tumors: value of MR angiography for preoperative planning and monitoring response to chemotherapy. AJR. American journal of roentgenology 1995. PMID: 7785572


  274. Ikenberg H, Matthay K, Schmitt B, Bauknecht T, Kiechle-Schwarz M, Göppinger A, Pfleiderer A. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer 1995. PMID: 8630877


  275. Matthay KK. Neuroblastoma: a clinical challenge and biologic puzzle. CA: a cancer journal for clinicians 1995. PMID: 7743421


  276. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, Reynolds CP. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995. PMID: 7707116


  277. Mentzer WC, Matthay K. Hematology and oncology. Current opinion in pediatrics 1995. PMID: 7728200


  278. Kalra R, Zoger S, Kosovich MS, Matthay KK. Radiological case of the month. Miliary pulmonary neuroblastoma. Archives of pediatrics & adolescent medicine 1995. PMID: 7849882


  279. Haase GM, Atkinson JB, Stram DO, Lukens JN, Matthay KK. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. Journal of pediatric surgery 1995. PMID: 7738753


  280. Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB, Haase GM, Stram DO, Seeger RC. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. European journal of cancer (Oxford, England : 1990) 1995. PMID: 7576971


  281. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary MC, Harris RE, Selch M, Atkinson JB, Haase GM, Ramsay NK. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994. PMID: 7964954


  282. Hattner RS, Pounds TR, Matthay KK. Normal cerebellar MIBG localization. Implications in the interpretation of delayed scans. Clinical nuclear medicine 1994. PMID: 7842595


  283. Mentzer WC, Matthay K. Hematology and oncology. Current opinion in pediatrics 1994. PMID: 8205173


  284. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary M, Harris RE, Selch M, Atkinson JB, Haase G, Hammond GD. Comparison of autologous and allogeneic bone marrow transplantation for neuroblastoma. Progress in clinical and biological research 1994. PMID: 7972225


  285. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Seeger RC. Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma. Progress in clinical and biological research 1994. PMID: 7972222


  286. Parisi MT, Hattner RS, Matthay KK, Berg BO, Sandler ED. Optimized diagnostic strategy for neuroblastoma in opsoclonus-myoclonus. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1993. PMID: 8229235


  287. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993. PMID: 8229138


  288. Campbell LA, Seeger RC, Harris RE, Villablanca JG, Matthay KK. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993. PMID: 8478657


  289. Parisi MT, Matthay KK, Huberty JP, Hattner RS. Neuroblastoma: dose-related sensitivity of MIBG scanning in detection. Radiology 1992. PMID: 1620849


  290. Iavarone A, Matthay KK, Steinkirchner TM, Israel MA. Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. Proceedings of the National Academy of Sciences of the United States of America 1992. PMID: 1349175


  291. Woodle MC, Matthay KK, Newman MS, Hidayat JE, Collins LR, Redemann C, Martin FJ, Papahadjopoulos D. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochimica et biophysica acta 1992. PMID: 1586658


  292. Halberg FE, Kramer JH, Moore IM, Wara WM, Matthay KK, Ablin AR. Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. International journal of radiation oncology, biology, physics 1992. PMID: 1727109


  293. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proceedings of the National Academy of Sciences of the United States of America 1991. PMID: 1763060


  294. D'Angio GJ, Matthay KK, Evans AE. Role of radiotherapy in neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991. PMID: 1941067


  295. Matthay KK. An overview on the treatment of neuroblastoma. Journal of nuclear biology and medicine (Turin, Italy : 1991) 1991. PMID: 1823813


  296. Matthay KK, Huberty JP, Hattner RS, Ablin AR, Engelstad BL, Zoger S, Hasegawa BH, Price D. Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. Journal of nuclear biology and medicine (Turin, Italy : 1991) 1991. PMID: 1823827


  297. D'Angio GJ, Matthay KK. Solid tumors in children. The New England journal of medicine 1991. PMID: 1870659


  298. Seeger RC, Villablanca JG, Matthay KK, Harris R, Moss TJ, Feig SA, Selch M, Ramsay N, Reynolds CP. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Progress in clinical and biological research 1991. PMID: 2068169


  299. Reynolds CP, Kane DJ, Einhorn PA, Matthay KK, Crouse VL, Wilbur JR, Shurin SB, Seeger RC. Response of neuroblastoma to retinoic acid in vitro and in vivo. Progress in clinical and biological research 1991. PMID: 2068138


  300. Halberg FE, Wara WM, Weaver KE, Wara DW, Ablin AR, Matthay KK, Mentzer WC, O'Leary MC, Cowan MJ. Total body irradiation and bone marrow transplantation for immunodeficiency disorders in young children. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1990. PMID: 2247633